Krystal reports strong Q2 2026 VYJUVEK revenue and updates pipeline outlook
Krystal Bio reported $119.2M in VYJUVEK revenue for Q2 2026, showcasing growing commercial traction. Maintaining a $1.1B cash balance, the company is on track for launches in Spain and Italy and advancing multiple registrations.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day